rehabРеабилитологияJournal of Medical Rehabilitation2949-58732949-5881IRBIS LLC10.17749/2949-5873/rehabil.2026.65rehab-152Research ArticleОБЗОРНЫЕ СТАТЬИREVIEW ARTICLESТехнологии искусственного интеллекта в реабилитации пациентов после системного противоопухолевого леченияArtificial intelligence technologies for patient rehabilitation after systemic anticancer therapyhttps://orcid.org/0000-0001-6132-9924КовалеваО. В.KovalevaO. V.

Ковалева Ольга Владимировна, д.б.н.

Каширское ш., д. 24, Москва 115522

WoS ResearcherID: T-6984-2017. Scopus Author ID: 36096645200

Olga V. Kovaleva, Dr. Sci. Biol.

WoS ResearcherID: T-6984-2017. Scopus Author ID: 36096645200

24 Kashirskoe Shosse, Moscow 115522

ovkovaleva@gmail.comФедеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава РоссииРоссияBlokhin National Medical Research Center of OncologyRussian Federation2026060720264154–62Copyright © Ковалева О.В., 20262026Ковалева О.В.Kovaleva O.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rehabilitology.com/jour/article/view/152

Во всем мире заболеваемость злокачественными новообразованиями неуклонно растет и остается одной из наиболее значимых медицинских проблем. В то же время совершенствование методов ранней диагностики и лечения приводит к увеличению числа пациентов, достигающих длительной или полной ремиссии. В связи с этим проблема медицинской реабилитации онкологических пациентов становится все более актуальной. Современное лечение злокачественных опухолей все чаще включает не только хирургическое вмешательство, но и системную лекарственную терапию, лучевую терапию, а также различные варианты их комбинированного применения. Несмотря на высокую эффективность данных методов, противоопухолевая терапия может сопровождаться развитием длительных функциональных нарушений. К наиболее частым осложнениям относятся снижение физической активности, хроническая усталость, когнитивные нарушения и другие состояния, которые влияют на качество жизни пациентов. В последние годы все больше исследований посвящено применению технологий искусственного интеллекта (ИИ) в медицине, включая реабилитацию. Использование алгоритмов машинного обучения, систем анализа биомедицинских данных, носимых устройств и цифровых платформ позволяет осуществлять мониторинг состояния пациентов и проводить индивидуализацию программ восстановления. Применение подобных технологий рассматривается как один из подходов к повышению эффективности реабилитации пациентов после противоопухолевого лечения. В обзоре рассматриваются направления применения технологий ИИ в реабилитации онкологических пациентов, включая цифровой мониторинг, телереабилитацию, системы анализа двигательной активности и когнитивную реабилитацию, а также обсуждаются перспективы дальнейшего развития данных технологий.

Globally, malignant neoplasms remain one of the most significant medical and social issues due to their increasing incidence.

Meanwhile, advances in early diagnosis and treatment methods have resulted in higher rates of long-term or complete remission among patients. Thus, medical rehabilitation for cancer patients becomes an important and relevant concern. As part of the modern treatment of malignant tumors, surgical intervention is often accompanied by systemic drug therapy, radiation therapy, or a combination of these approaches. Despite their high efficacy, these methods may result in long-term functional impairments. The most common complications include reduced physical activity, chronic fatigue, cognitive impairment, and other conditions that decrease patients’ quality of life. Recent studies emphasize the application of artificial intelligence (AI) technologies in medicine, including rehabilitation. Machine learning algorithms, biomedical data analysis systems, wearable devices, and digital platforms make it possible to monitor patients' conditions, thus individualizing rehabilitation programs. These technologies are therefore considered a promising approach to improving the effectiveness of rehabilitation for patients after anticancer treatment. This review discusses current approaches to using AI technologies to rehabilitate cancer patients after treatment. Particularly, it covers digital monitoring, telerehabilitation, systems for analyzing motor activity, and cognitive rehabilitation. The review also outlines prospects for further developing these technologies.

искусственный интеллектонкологическая реабилитациясистемная противоопухолевая терапияцифровое здравоохранениетелереабилитацияносимые сенсорные устройствакачество жизниartificial intelligencecancer rehabilitationsystemic anticancer therapydigital healthtelerehabilitationwearable devicesquality of lifeReferencesShuel S.L. Targeted cancer therapies: clinical pearls for primary care. Can Fam Physician. 2022; 68 (7): 515–8. https://doi.org/10.46747/cfp.6807515.Shuel S.L. Targeted cancer therapies: clinical pearls for primary care. Can Fam Physician. 2022; 68 (7): 515–8. https://doi.org/10.46747/cfp.6807515.Tan S., Li D., Zhu X. Cancer immunotherapy: pros, cons and beyond. Biomed Pharmacother. 2020; 124: 109821. https://doi.org/10.1016/j.biopha.2020.109821.Tan S., Li D., Zhu X. Cancer immunotherapy: pros, cons and beyond. Biomed Pharmacother. 2020; 124: 109821. https://doi.org/10.1016/j.biopha.2020.109821.Basak D., Arrighi S., Darwiche Y., Deb S. Comparison of anticancer drug toxicities: paradigm shift in adverse effect profile. Life. 2021; 12 (1): 48. https://doi.org/10.3390/life12010048.Basak D., Arrighi S., Darwiche Y., Deb S. Comparison of anticancer drug toxicities: paradigm shift in adverse effect profile. Life. 2021; 12 (1): 48. https://doi.org/10.3390/life12010048.Anand U., Dey A., Chandel A.K.S., et al. Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 2023; 10 (4): 1367–401. https://doi.org/10.1016/j.gendis.2022.02.007.Anand U., Dey A., Chandel A.K.S., et al. Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 2023; 10 (4): 1367–401. https://doi.org/10.1016/j.gendis.2022.02.007.Tilsed C.M., Fisher S.A., Nowak A.K., et al. Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action. Front Oncol. 2022; 12: 960317. https://doi.org/10.3389/fonc.2022.960317.Tilsed C.M., Fisher S.A., Nowak A.K., et al. Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action. Front Oncol. 2022; 12: 960317. https://doi.org/10.3389/fonc.2022.960317.Васильева Е.Б., Ростовцев Д.М., Толпейкина К.А. и др. Клинический опыт применения препарата ленватиниб в неоадъювантном режиме при лечении нерезектабельного дифференцированного рака щитовидной железы. Oпухоли головы и шеи. 2024; 14 (1): 10–5. https://doi.org/10.17650/2222-1468-2024-14-1-10-15.Vasilyeva E.B., Rostovtsev D.M., Tolpeikina K.A., et al. Clinical experience in the neoadjuvant treatment of unresectable differentiated thyroid cancer with the lenvatinib. Opukholi golovy i shei / Head and Neck Tumors. 2024; 14 (1): 10–5 (in Russ.). https://doi.org/10.17650/2222-1468-2024-14-1-10-15.Astolfi L., Ghiselli S., Guaran V., et al. Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: a retrospective evaluation. Oncol Rep. 2013; 29 (4): 1285–92. https://doi.org/10.3892/or.2013.2279.Astolfi L., Ghiselli S., Guaran V., et al. Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: a retrospective evaluation. Oncol Rep. 2013; 29 (4): 1285–92. https://doi.org/10.3892/or.2013.2279.Radeva L., Yoncheva K. Doxorubicin toxicity and recent approaches to alleviating its adverse effects with focus on oxidative stress. Molecules. 2025; 30 (15): 3311. https://doi.org/10.3390/molecules30153311.Radeva L., Yoncheva K. Doxorubicin toxicity and recent approaches to alleviating its adverse effects with focus on oxidative stress. Molecules. 2025; 30 (15): 3311. https://doi.org/10.3390/molecules30153311.Lai J.I., Chao T.C., Liu C.Y., et al. A systemic review of taxanes and their side effects in metastatic breast cancer. Front Oncol. 2022; 12: 940239. https://doi.org/10.3389/fonc.2022.940239.Lai J.I., Chao T.C., Liu C.Y., et al. A systemic review of taxanes and their side effects in metastatic breast cancer. Front Oncol. 2022; 12: 940239. https://doi.org/10.3389/fonc.2022.940239.Macdonald J.S. Toxicity of 5-fluorouracil. Oncology. 1999; 13 (7 Suppl. 3): 33–4.Macdonald J.S. Toxicity of 5-fluorouracil. Oncology. 1999; 13 (7 Suppl. 3): 33–4.Ahles T.A., Saykin A.J. Candidate mechanisms for chemotherapyinduced cognitive changes. Nat Rev Cancer. 2007; 7 (3): 192–201. https://doi.org/10.1038/nrc2073.Ahles T.A., Saykin A.J. Candidate mechanisms for chemotherapyinduced cognitive changes. Nat Rev Cancer. 2007; 7 (3): 192–201. https://doi.org/10.1038/nrc2073.Montoya S., Soong D., Nguyen N., et al. Targeted therapies in cancer: to be or not to be, selective. Biomedicines. 2021; 9 (11): 1591. https://doi.org/10.3390/biomedicines9111591.Montoya S., Soong D., Nguyen N., et al. Targeted therapies in cancer: to be or not to be, selective. Biomedicines. 2021; 9 (11): 1591. https://doi.org/10.3390/biomedicines9111591.Press M.F., Lenz H.J. EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Drugs. 2007; 67 (14): 2045–75. https://doi.org/10.2165/00003495-200767140-00006.Press M.F., Lenz H.J. EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Drugs. 2007; 67 (14): 2045–75. https://doi.org/10.2165/00003495-200767140-00006.Hirsh V. Managing treatment-related adverse events associated with EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer. Curr Oncol. 2011; 18 (3): 126–38. https://doi.org/10.3747/co.v18i3.877.Hirsh V. Managing treatment-related adverse events associated with EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer. Curr Oncol. 2011; 18 (3): 126–38. https://doi.org/10.3747/co.v18i3.877.Schmidinger M. Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors. EJC Suppl. 2013; 11 (2): 172–91. https://doi.org/10.1016/j.ejcsup.2013.07.016.Schmidinger M. Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors. EJC Suppl. 2013; 11 (2): 172–91. https://doi.org/10.1016/j.ejcsup.2013.07.016.Dawoud E., Azribi F., Chehal A., et al. Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensus. Front Oncol. 2025; 14: 1443962. https://doi.org/10.3389/fonc.2024.1443962.Dawoud E., Azribi F., Chehal A., et al. Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensus. Front Oncol. 2025; 14: 1443962. https://doi.org/10.3389/fonc.2024.1443962.Кзыргалин Ш.Р., Ямиданов Р.С., Назмиева К.А., Ганцев Ш.Х. Обзор низкомолекулярных противоопухолевых NF-κB-ингибиторов. Креативная хирургия и онкология. 2023; 13 (2): 143–50. https://doi.org/10.24060/2076-3093-2023-13-2-143-150.Kzyrgalin Sh.R., Yamidanov R.S., Nazmieva K.A., Gantsev Sh.Kh. Review of small molecule anticancer NF-κB inhibitors. Creative Surgery and Oncology. 2023; 13 (2): 143–50 (in Russ.). https://doi.org/10.24060/2076-3093-2023-13-2-143-150.Esfahani K., Roudaia L., Buhlaiga N., et al. A review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol. 2020; 27 (Suppl. 2): S87–97. https://doi.org/10.3747/co.27.5223.Esfahani K., Roudaia L., Buhlaiga N., et al. A review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol. 2020; 27 (Suppl. 2): S87–97. https://doi.org/10.3747/co.27.5223.Авдеева Ж.И., Солдатов А.А., Алпатова Н.А. и др. Исследования иммуногенности терапевтических белков: методические аспекты выявления и изучения антител к лекарственному препарату. Иммунология. 2024; 45 (1): 91–106. https://doi.org/10.33029/18162134-2024-45-1-91-106.Avdeeva Zh.I., Soldatov A.A., Alpatova N.A. et al. Studies on the immunogenicity of therapeutic proteins: methodological aspects of identifying and studying of the anti-drug antibodies. Immunologiya. 2024; 45 (1): 91–106 (in Russ.). https://doi.org/10.33029/1816-21342024-45-1-91-106.Yin Q., Wu L., Han L., et al. Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol. 2023; 14: 1167975. https://doi.org/10.3389/fimmu.2023.1167975.Yin Q., Wu L., Han L., et al. Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol. 2023; 14: 1167975. https://doi.org/10.3389/fimmu.2023.1167975.Tremont A., Lu J., Cole J.T. Endocrine therapy for early breast cancer: updated review. Ochsner J. 2017; 17 (4): 405–11.Tremont A., Lu J., Cole J.T. Endocrine therapy for early breast cancer: updated review. Ochsner J. 2017; 17 (4): 405–11.Connolly R.M., Carducci M.A., Antonarakis E.S. Use of androgen deprivation therapy in prostate cancer: indications and prevalence. Asian J Androl. 2012; 14 (2): 177–86. https://doi.org/10.1038/aja.2011.103.Connolly R.M., Carducci M.A., Antonarakis E.S. Use of androgen deprivation therapy in prostate cancer: indications and prevalence. Asian J Androl. 2012; 14 (2): 177–86. https://doi.org/10.1038/aja.2011.103.Andreu Y., Soto-Rubio A., Ramos-Campos M., et al. Impact of hormone therapy side effects on health-related quality of life, distress, and well-being of breast cancer survivors. Sci Rep. 2022; 12 (1): 18673. https://doi.org/10.1038/s41598-022-22971-x.Andreu Y., Soto-Rubio A., Ramos-Campos M., et al. Impact of hormone therapy side effects on health-related quality of life, distress, and well-being of breast cancer survivors. Sci Rep. 2022; 12 (1): 18673. https://doi.org/10.1038/s41598-022-22971-x.Smith S.R., Zheng J.Y., Silver J., et al. Cancer rehabilitation as an essential component of quality care and survivorship from an international perspective. Disabil Rehabil. 2020; 42 (1): 8–13. https://doi.org/10.1080/09638288.2018.1514662.Smith S.R., Zheng J.Y., Silver J., et al. Cancer rehabilitation as an essential component of quality care and survivorship from an international perspective. Disabil Rehabil. 2020; 42 (1): 8–13. https://doi.org/10.1080/09638288.2018.1514662.Campbell K.L., Winters-Stone K.M., Wiskemann J., et al. Exercise guidelines for cancer survivors: consensus statement from international multidisciplinary roundtable. Med Sci Sports Exerc. 2019; 51 (11): 2375–90. https://doi.org/10.1249/MSS.0000000000002116Campbell K.L., Winters-Stone K.M., Wiskemann J., et al. Exercise guidelines for cancer survivors: consensus statement from international multidisciplinary roundtable. Med Sci Sports Exerc. 2019; 51 (11): 2375–90. https://doi.org/10.1249/MSS.0000000000002116Мирошникова А.С., Петриченко А.В., Острейков И.Ф. и др. Опыт достижения положительных результатов реабилитационных мероприятий у ребeнка с болезнью фон Гиппеля–Линдау в послеоперационном периоде радикального удаления гемангиобластомы мозжечка: клинический случай. Физическая и реабилитационная медицина, медицинская реабилитация. 2025; 7 (4): 313–22. https://doi.org/10.36425/rehab694067.Miroshnikova A.S., Petrichenko А.V., Ostreikov I.F., et al. Achieving positive rehabilitation outcomes in a child with Von Hippel–Lindau disease following complete resection of a cerebellar hemangioblastoma: a case report. Physical and Rehabilitation Medicine, Medical Rehabilitation. 2025; 7 (4): 313–22 (in Russ.). https://doi.org/10.36425/rehab694067.Арингазина А.М., Олжаев С.Т., Хегай Б.С. Реабилитация в онкологии. Профилактическая медицина. 2019; 22 (5): 131–5. https://doi.org/10.17116/profmed201922051131.Aringazina A.M., Olzhayev S.T., Khegay B.S. Rehabilitation in oncology. Russian Journal of Preventive Medicine. 2019; 22 (5): 131–5 (in Russ.). https://doi.org/10.17116/profmed201922051131.Wang L., Ho M.H., Choi E.P.H., et al. Effectiveness of cognitive rehabilitation in improving subjective and objective cognitive functions in cancer patients: a systematic review, pairwise, and network meta-analysis of randomized controlled trials. Int J Nurs Stud. 2026; 174: 105298. https://doi.org/10.1016/j.ijnurstu.2025.105298.Wang L., Ho M.H., Choi E.P.H., et al. Effectiveness of cognitive rehabilitation in improving subjective and objective cognitive functions in cancer patients: a systematic review, pairwise, and network meta-analysis of randomized controlled trials. Int J Nurs Stud. 2026; 174: 105298. https://doi.org/10.1016/j.ijnurstu.2025.105298.Weis J. Psychosocial care for cancer patients. Breast Care. 2015; 10 (2): 84–6. https://doi.org/10.1159/000381969.Weis J. Psychosocial care for cancer patients. Breast Care. 2015; 10 (2): 84–6. https://doi.org/10.1159/000381969.Basch E., Deal A.M., Dueck A.C., et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA. 2017; 318 (2): 197–8. https://doi.org/10.1001/jama.2017.7156.Basch E., Deal A.M., Dueck A.C., et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA. 2017; 318 (2): 197–8. https://doi.org/10.1001/jama.2017.7156.Мурашко М.А., Ваньков В.В., Панин А.И. и др. Внедрение технологий искусственного интеллекта в здравоохранении России: итоги 2024 г. Национальное здравоохранение. 2025; 6 (3): 6–19. https://doi.org/10.47093/2713-069X.2025.6.3.6-19.Murashko M.A., Vankov V.V., Panin A.I., et al. Implementation of artificial intelligence technologies in healthcare in Russia: results of 2024. National Health Care (Russia). 2025; 6 (3): 6–19 (in Russ.). https://doi.org/10.47093/2713-069X.2025.6.3.6-19.Корабельников Д.И., Ламоткин А.И. Искусственный интеллект в онкологии: мировой опыт использования и перспективы развития. ФАРМАКОЭКОНОМИКА Современная фармакоэкономика и фармакоэпидемиология. 2025; 18 (3): 437–47. https://doi.org/10.17749/2070-4909/farmakoekonomika.2025.302.Korabelnikov D.I., Lamotkin A.I. Artificial intelligence in oncology: global experience and future prospects. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2025; 18 (3): 437–47 (in Russ.). https://doi.org/10.17749/2070-4909/farmakoekonomika.2025.302.Суфэльфа А.Р., Петрищева К.Н., Щербина К.К. и др. Искусственный интеллект в комплексной реабилитации инвалидов. Вопросы курортологии, физиотерапии и лечебной физической культуры. 2025; 102 (3): 54–61. https://doi.org/10.17116/kurort202510203154.Sufelfa A.R., Petrishcheva K.N., Shcherbina K.K., et al. Artificial intelligence in comprehensive rehabilitation of people with disabilities. (Literature review). Problems of Balneology, Physiotherapy and Exercise Therapy. 2025; 102 (3): 54–61 (in Russ.). https://doi.org/10.17116/kurort202510203154.Hao J. Harnessing artificial intelligence for cancer rehabilitation: a call to action. Support Care Cancer. 2025; 33 (11): 961. https://doi.org/10.1007/s00520-025-10047-1.Hao J. Harnessing artificial intelligence for cancer rehabilitation: a call to action. Support Care Cancer. 2025; 33 (11): 961. https://doi.org/10.1007/s00520-025-10047-1.Piwek L., Ellis D.A., Andrews S., Joinson A. The rise of consumer health wearables: promises and barriers. PLoS Med. 2016; 13 (2): e1001953. https://doi.org/10.1371/journal.pmed.1001953.Piwek L., Ellis D.A., Andrews S., Joinson A. The rise of consumer health wearables: promises and barriers. PLoS Med. 2016; 13 (2): e1001953. https://doi.org/10.1371/journal.pmed.1001953.Topol E.J. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019; 25 (1): 44–56. https://doi.org/10.1038/s41591-018-0300-7.Topol E.J. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019; 25 (1): 44–56. https://doi.org/10.1038/s41591-018-0300-7.Goncalves Leite Rocco P., Reategui-Rivera C.M., Finkelstein J. Telemedicine applications for cancer rehabilitation: scoping review. JMIR Cancer. 2024; 10: e56969. https://doi.org/10.2196/56969.Goncalves Leite Rocco P., Reategui-Rivera C.M., Finkelstein J. Telemedicine applications for cancer rehabilitation: scoping review. JMIR Cancer. 2024; 10: e56969. https://doi.org/10.2196/56969.Batalik L., Chamradova K., Winnige P., et al. Effect of exercise-based cancer rehabilitation via telehealth: a systematic review and metaanalysis. BMC Cancer. 2024; 24 (1): 600. https://doi.org/10.1186/s12885-024-12348-w.Batalik L., Chamradova K., Winnige P., et al. Effect of exercise-based cancer rehabilitation via telehealth: a systematic review and metaanalysis. BMC Cancer. 2024; 24 (1): 600. https://doi.org/10.1186/s12885-024-12348-w.Dennett A., Harding K.E., Reimert J., et al. Telerehabilitation's safety, feasibility, and exercise uptake in cancer survivors: process evaluation. JMIR Cancer. 2021; 7 (4): e33130. https://doi.org/10.2196/33130.Dennett A., Harding K.E., Reimert J., et al. Telerehabilitation's safety, feasibility, and exercise uptake in cancer survivors: process evaluation. JMIR Cancer. 2021; 7 (4): e33130. https://doi.org/10.2196/33130.Sumner J., Lim H.W., Chong L.S., et al. Artificial intelligence in physical rehabilitation: a systematic review. Artif Intell Med. 2023; 146: 102693. https://doi.org/10.1016/j.artmed.2023.102693.Sumner J., Lim H.W., Chong L.S., et al. Artificial intelligence in physical rehabilitation: a systematic review. Artif Intell Med. 2023; 146: 102693. https://doi.org/10.1016/j.artmed.2023.102693.Capetti B., Sdinami S., Luisi J., et al. Efficacy of technology-based cognitive rehabilitation tools for cancer-related cognitive impairment in non-CNS cancer patients: a systematic review. Healthcare. 2026; 14 (2): 239. https://doi.org/10.3390/healthcare14020239.Capetti B., Sdinami S., Luisi J., et al. Efficacy of technology-based cognitive rehabilitation tools for cancer-related cognitive impairment in non-CNS cancer patients: a systematic review. Healthcare. 2026; 14 (2): 239. https://doi.org/10.3390/healthcare14020239.Zeng Y., Zeng L., Cheng A.S.K., et al. The use of immersive virtual reality for cancer-related cognitive impairment assessment and rehabilitation: a clinical feasibility study. Asia Pac J Oncol Nurs. 2022; 9 (12): 100079. https://doi.org/10.1016/j.apjon.2022.100079.Zeng Y., Zeng L., Cheng A.S.K., et al. The use of immersive virtual reality for cancer-related cognitive impairment assessment and rehabilitation: a clinical feasibility study. Asia Pac J Oncol Nurs. 2022; 9 (12): 100079. https://doi.org/10.1016/j.apjon.2022.100079.

The authors declare that there are no conflicts of interest present.